+Compare
GERN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.13B

GERN Geron Corp Forecast, Technical & Fundamental Analysis

a developer of therapeutic products for cancer

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for GERN with price predictions
08:00 PM EDT Sep 21, 2023

GERN's Indicator enters downward trend

The Aroon Indicator for GERN entered a downward trend on September 22, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 270 similar instances where the Aroon Indicator formed such a pattern. In of the 270 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 11, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on GERN as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for GERN moved below the 200-day moving average on September 19, 2023. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for GERN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for GERN just turned positive on September 21, 2023. Looking at past instances where GERN's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .

GERN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.771) is normal, around the industry mean (22.655). P/E Ratio (0.000) is within average values for comparable stocks, (131.527). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.920). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. GERN's P/S Ratio (2500.000) is slightly higher than the industry average of (308.747).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 410.28B. NVO holds the highest valuation in this group at 410.28B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was 32%, and the average quarterly price growth was 32%. SKYED experienced the highest price growth at 81%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

GERN is expected to report earnings to fall 65.52% to -10 cents per share on November 08

Geron Corp GERN Stock Earnings Reports
Q3'23
Est.
$-0.10
Q2'23
Missed
by $0.21
Q1'23
Beat
by $0.03
Q4'22
Beat
by $0.02
Q3'22
Missed
by $0.01
The last earnings report on August 03 showed earnings per share of -28 cents, missing the estimate of -7 cents. With 4.12M shares outstanding, the current market capitalization sits at 1.13B.
A.I. Advisor
published General Information

General Information

a developer of therapeutic products for cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
919 East Hillsdale Boulevard
Phone
+1 650 473-7700
Employees
107
Web
https://www.geron.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDYNX92.640.11
+0.12%
Franklin DynaTech C
LPFAX5.95N/A
N/A
ALPS Global Opportunity A
MOPIX20.43-0.04
-0.20%
MainStay WMC Small Companies I
JAWGX54.91-0.11
-0.20%
Janus Henderson VIT Global Rsrch Instl
CMVYX11.63-0.03
-0.26%
Columbia Select Mid Cap Value Instl 3

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with MDGL. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-0.92%
MDGL - GERN
54%
Loosely correlated
-3.87%
CLDX - GERN
43%
Loosely correlated
-3.01%
VYNE - GERN
40%
Loosely correlated
+0.29%
KRON - GERN
38%
Loosely correlated
N/A
RARE - GERN
38%
Loosely correlated
-0.49%
More

Groups containing GERN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-0.92%
cancer
(undefined stocks)
37%
Loosely correlated
-1.34%
biotechnology
(undefined stocks)
33%
Loosely correlated
-0.81%
drugs
(undefined stocks)
33%
Poorly correlated
-0.89%
therapeutics
(undefined stocks)
31%
Poorly correlated
-1.01%